



(51) International Patent Classification:

C07D 413/04 (2006.01) *C07D 498/10* (2006.01)
C07D 413/14 (2006.01) *C07D 513/04* (2006.01)
C07D 417/14 (2006.01) *A61K 31/506* (2006.01)
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:

PCT/IB2012/055133

(22) International Filing Date:

26 September 2012 (26.09.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/539,553 27 September 2011 (27.09.2011) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).


(72) Inventors; and

(71) Applicants (for US only): **CHO, Young Shin** [KR/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **LEVELL, Julian Roy** [GB/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **TOURE, Bakary-Barry** [CA/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **YANG, Fan** [CN/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **CA-**

FERRO, Thomas [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **LEI, Huangshu** [US/CN]; No. 565, Tushan Rd., Nan'an District, Chongqing 400061 (CN). **LENOIR, Francois** [CA/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **LIU, Gang** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **PALERMO, Mark G.** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **SHULTZ, Michael David** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **SMITH, Troy** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **COSTALES, Abran Q.** [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). **PFISTER, Keith Bruce** [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). **SENDZIK, Martin** [DE/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). **SHAFER, Cynthia** [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). **SUTTON, James** [US/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US). **ZHAO, Qian** [CN/US]; Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Emeryville, California 94608-2916 (US).

[Continued on next page]

(54) Title: 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH



(57) Abstract: The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R¹-R⁶ are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.



(74) **Agent: MADDEN, Laura**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))